PeptidePreclinical
PE-22-28
Also known as: Mini-Spadin
TREK-1 Channel Blocker | Shortened Spadin Analog
Overview
Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects.
Key benefits
- Rapid antidepressant effects within 4 days (preclinical)
- Hippocampal neurogenesis and synaptogenesis
- Enhanced serotonergic neurotransmission
- Extended ~23 hour duration of action
- 300-500x greater potency than full-length Spadin
Mechanism of action
Selectively blocks TREK-1 potassium channels (IC50: 0.12 nM). Enhances serotonin neurotransmission in dorsal raphe nucleus, triggering CREB activation and hippocampal neurogenesis.
Molecular data
- Type
- Linear heptapeptide
- Half-life
- Approximately 23 hours
Sequence
Gly-Val-Ser-Trp-Gly-Leu-Arg (GVSWGLR)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Mental Health
Neurogenesis
Cognition
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 50-200mcg | Once daily | — |
| — | 100-200mcg | Once daily | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | Higher than injectable (specific dose TBD) | Daily | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 100-300mcg (estimated) | Daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- No effects on TREK-2, TRAAK, TASK-1 channels observed
- No cardiac dysfunction or seizures in preclinical studies
Contraindications
- Pregnancy and breastfeeding
- Concurrent MAOI use
Monitoring
- Research compound only - not FDA-approved
- Unknown long-term human effects
- Monitor for serotonin syndrome if combined with serotonergic medications